Form4insider filings, from the source

SEC Form 4 · accession 0001562180-17-003379

BIO-TECHNE Corp · TECH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Norman David Eansor
Officer — SVP - Novus Biologicals
Period of report
Oct 30, 2017
Accepted (ET)
Oct 30, 2017 · 4:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000842023

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stockholding———3,402D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Restricted Stock UnitsF1,F2—Oct 26, 2017A2,174A——Common Stock2,1742,174D
Stock Options (Right to buy)F2$125.05Oct 26, 2017A11,982A—Aug 9, 2024Common Stock11,98211,982D
Stock Options (Right to buy)F3$125.05Oct 26, 2017A15,976A—Aug 9, 2024Common Stock15,97615,976D
Restricted Stock UnitsF1,F4—holding—————Common Stock1,5001,500D
Restricted Stock UnitsF1,F5—holding—————Common Stock2,2872,287D
Stock Option (Right to Buy)F6$108.49holding————Aug 7, 2022Common Stock12,50012,500D
Stock Option (Right to Buy)F4$108.49holding————Aug 7, 2022Common Stock9,3759,375D
Stock Option (Right to Buy)F7$94.35holding————Aug 12, 2021Common Stock15,00015,000D
Stock Options (Right to buy)F8$106.59holding————Aug 18, 2023Common Stock18,81918,819D
Stock Options (Right to buy)F5$106.59holding————Aug 18, 2023Common Stock14,11414,114D

Explanation of responses